Key Highlights
- Hydralyte LLC recorded a maiden monthly operating profit of US$4,300 in August 2026 on Revenue of US$234,000
- Quarterly operating loss fell 85% to US$66,900, with net loss after tax down 92% to US$35,700
- Total operating expenses declined 58% to US$313,900 as the cost-reduction program took full effect
- Revenue per Advertising dollar increased 71% to US$3.90, with advertising spend cut 54% to US$170,600
The Hydration Pharmaceuticals Company Limited(ASX:HPC) reported a material improvement in the financial performance of its Hydralyte LLC Subsidiary during the September 2026 quarter, highlighted by the Business achieving its first-ever monthly operating profit in August 2026.
Hydralyte LLC, the company's wholly owned US operating subsidiary, generated an operating profit of US$4,300 in August on revenue of US$234,000. For the full quarter, the operating loss was US$66,900, an 85% reduction from US$446,500 in the prior corresponding period. Net loss after tax fell 92% to US$35,700.
What Drove the Improvement in Financial Performance?
The cost-reduction program initiated earlier in 2026 was fully reflected in the quarterly numbers. Total operating expenses fell 58% to US$313,900 from US$746,400 in Q3 CY25. The key expense line items showed substantial declines: advertising and Marketing expenditure was reduced 54% to US$170,600, staff costs fell 70% to US$66,800, and other operating costs declined 49% to US$76,600.
Operating costs excluding advertising were running at approximately US$48,000 per month at quarter-end, compared with approximately US$124,000 per month in the prior corresponding period. At this cost level, Hydralyte LLC demonstrated it could be profitable at monthly revenue of US$234,000.
Advertising efficiency also improved materially, with each dollar of advertising generating US$3.90 of revenue, compared with US$2.28 a year earlier. The company concentrated spend on the highest-returning Amazon placements while largely discontinuing lower-return channels.
What Happened With Revenue and Stock Availability?
Revenue for the quarter was US$665,200, down 22% on the prior corresponding period. September was affected by stock-outs in the retail channel, resulting in estimated lost sales of approximately US$59,000. Amazon revenue was US$438,400 and retail channel revenue via Emerson Healthcare was US$146,000.
Adjusting for the September retail disruption, underlying revenue decline was approximately 15% — against a 54% cut in advertising spend. Stock has been replenished and the company entered the December quarter fully stocked across its channels.
Gross Margin held at 65% for the quarter, with August achieving a 73% gross margin.
What Was the Cash Flow Position?
Net operating cash outflow was US$249,500 for the quarter, down 27% from US$343,500 in Q2 CY26. The quarter included US$158,600 of payments for inventory and packaging to restore stock availability, plus US$50,000 in settlements of prior-period invoices. Cash at 30 September 2026 was US$173,400. Post quarter-end, the company announced a pro-rata rights issue to fund the business through to sustainable profitability.
Where Does HPC Stand Going Forward?
HPC enters the December 2026 quarter with its cost base reset, full stock availability restored across channels, and a demonstrated path to monthly profitability. The rights issue will be a determining Factor in the company's ability to sustain operations through to breakeven on a consistent quarterly basis.






Please wait processing your request...